INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 40 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $2,376,000 | -10.2% | 2,666,000 | 0.0% | 0.02% | -11.8% |
| Q1 2019 | $2,645,000 | +7.3% | 2,666,000 | 0.0% | 0.02% | 0.0% |
| Q4 2018 | $2,465,000 | -22.8% | 2,666,000 | -15.8% | 0.02% | -5.6% |
| Q3 2018 | $3,194,000 | +14.7% | 3,166,000 | 0.0% | 0.02% | +12.5% |
| Q2 2018 | $2,784,000 | +8.9% | 3,166,000 | 0.0% | 0.02% | +6.7% |
| Q1 2018 | $2,556,000 | +0.1% | 3,166,000 | 0.0% | 0.02% | 0.0% |
| Q4 2017 | $2,554,000 | -17.3% | 3,166,000 | -20.8% | 0.02% | -16.7% |
| Q3 2017 | $3,090,000 | -20.6% | 4,000,000 | 0.0% | 0.02% | -21.7% |
| Q2 2017 | $3,890,000 | +4.3% | 4,000,000 | 0.0% | 0.02% | +4.5% |
| Q1 2017 | $3,728,000 | +93.1% | 4,000,000 | +84.6% | 0.02% | +100.0% |
| Q4 2016 | $1,931,000 | +15.1% | 2,167,000 | +44.5% | 0.01% | +10.0% |
| Q3 2016 | $1,677,000 | – | 1,500,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Worth Venture Partners, LLC | 5,324,000 | $4,995,000 | 3.78% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $53,020,000 | 2.12% |
| DLD Asset Management, LP | 32,500,000 | $30,048,000 | 2.06% |
| Castle Creek Arbitrage, LLC | 4,504,000 | $4,161,000 | 1.43% |
| TENOR CAPITAL MANAGEMENT Co., L.P. | 10,000,000 | $9,372,000 | 0.62% |
| Graham Capital Management, L.P. | 14,636,000 | $13,509,000 | 0.60% |
| OAKTREE CAPITAL MANAGEMENT LP | 64,452,000 | $59,704,000 | 0.54% |
| Context Capital Management, LLC | 1,000,000 | $926,000 | 0.52% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 23,118,000 | $21,341,000 | 0.52% |
| WOLVERINE ASSET MANAGEMENT LLC | 18,583,000 | $17,322,000 | 0.21% |